Liver Resection in Selective Hepatocellular Carcinoma with Vp3 or Vp4 Portal Vein Tumor Thrombosis Improves Prognosis

Overview

Journal J Liver Cancer

Date 2024 Feb 14

PMID 38351676

Authors

Manuel Lim

Jongman Kim

Jinsoo Rhu

Gyu-Seong Choi

Jae-Won Joh

Affiliations

Soon will be listed here.

Abstract

Background/aim: Hepatocellular carcinoma (HCC) tumor thrombi located in the first branch of the portal vein (Vp3) or in the main portal trunk (Vp4) are associated with poor prognosis. This study aimed to investigate the clinicopathological characteristics and risk factors for HCC recurrence and mortality following liver resection (LR) in patients with Vp3 or Vp4 HCC.

Methods: The study included 64 patients who underwent LR for HCC with Vp3 or Vp4 portal vein tumor thrombosis (PVTT).

Results: Fifty-eight patients (90.6%) had Vp3 PVTT, whereas the remaining six patients exhibited Vp4 PVTT. The median tumor size measured 8 cm, with approximately 36% of patients presented with multiple tumors. Fifty-four patients (84.4%) underwent open LR, whereas 10 patients underwent laparoscopic LR. In the Vp4 cases, combined LR and tumor thrombectomy were performed. The 3-year cumulative disease-free survival rate was 42.8% for the Vp3 group and 22.2% for the Vp4 group. The overall survival (OS) rate at 3 years was 47.9% for the Vp3 group and 60.0% for the Vp4 group. Intrahepatic metastasis has been identified as an important contributor to HCC recurrence. High hemoglobin levels are associated with high mortality.

Conclusion: LR is a safe and effective treatment modality for selected patients with Vp3 or Vp4 HCC PVTT. This suggests that LR is a viable option for these patients, with favorable outcomes in terms of OS.

References

Kondo K, Chijiiwa K, Kai M, Otani K, Nagaike K, Ohuchida J . Surgical strategy for hepatocellular carcinoma patients with portal vein tumor thrombus based on prognostic factors. J Gastrointest Surg. 2009; 13(6):1078-83. DOI: 10.1007/s11605-009-0854-2. View

Inoue Y, Hasegawa K, Ishizawa T, Aoki T, Sano K, Beck Y . Is there any difference in survival according to the portal tumor thrombectomy method in patients with hepatocellular carcinoma?. Surgery. 2008; 145(1):9-19. DOI: 10.1016/j.surg.2008.09.005. View

EDMONDSON H, STEINER P . Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer. 1954; 7(3):462-503. DOI: 10.1002/1097-0142(195405)7:3<462::aid-cncr2820070308>3.0.co;2-e. View

Han S, Kim J, Choi G, Park J, Kwon C, Kim S . Protrusion of hepatocellular carcinoma is a predictor of early recurrence in hepatectomy patients after spontaneous rupture. Ann Surg Treat Res. 2016; 91(1):17-22. PMC: 4942534. DOI: 10.4174/astr.2016.91.1.17. View

Jin S, Choi W, Shim J, Lee D, Kim K, Lim Y . Subclassification of advanced-stage hepatocellular carcinoma with macrovascular invasion: combined transarterial chemoembolization and radiotherapy as an alternative first-line treatment. J Liver Cancer. 2023; 23(1):177-188. PMC: 10202243. DOI: 10.17998/jlc.2023.03.04. View

Wei X, Jiang Y, Zhang X, Feng S, Zhou B, Ye X . Neoadjuvant Three-Dimensional Conformal Radiotherapy for Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Randomized, Open-Label, Multicenter Controlled Study. J Clin Oncol. 2019; 37(24):2141-2151. PMC: 6698917. DOI: 10.1200/JCO.18.02184. View

. 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Clin Mol Hepatol. 2022; 28(4):583-705. PMC: 9597235. DOI: 10.3350/cmh.2022.0294. View

Aapro M, Osterborg A, Gascon P, Ludwig H, Beguin Y . Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron. Ann Oncol. 2012; 23(8):1954-1962. DOI: 10.1093/annonc/mds112. View

Jonas S, Bechstein W, Steinmuller T, Herrmann M, Radke C, Berg T . Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology. 2001; 33(5):1080-6. DOI: 10.1053/jhep.2001.23561. View

10.

Yoon S, Ryoo B, Lee S, Kim J, Shin J, An J . Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical Trial. JAMA Oncol. 2018; 4(5):661-669. PMC: 5885246. DOI: 10.1001/jamaoncol.2017.5847. View

11.

Yun S, Kim J, Rhu J, Choi G, Joh J . Fibrosis-4 index, a predictor for prognosis of hepatocellular carcinoma patients after curative hepatectomy even in hepatitis B virus dominant populations. Ann Surg Treat Res. 2023; 104(4):195-204. PMC: 10083349. DOI: 10.4174/astr.2023.104.4.195. View

12.

Trotter J, Cohn A, Grant R . Erythrocytosis in a patient with hepatocellular carcinoma. J Clin Gastroenterol. 2002; 35(4):365-6. DOI: 10.1097/00004836-200210000-00022. View

13.

Llovet J, Burroughs A, Bruix J . Hepatocellular carcinoma. Lancet. 2003; 362(9399):1907-17. DOI: 10.1016/S0140-6736(03)14964-1. View

14.

Ikai I, Yamamoto Y, Yamamoto N, Terajima H, Hatano E, Shimahara Y . Results of hepatic resection for hepatocellular carcinoma invading major portal and/or hepatic veins. Surg Oncol Clin N Am. 2003; 12(1):65-75, ix. DOI: 10.1016/s1055-3207(02)00082-0. View

15.

Lee S, Song S, Bae B, Park Y . Comparing efficacies of different treatment regimens in patients with hepatocellular carcinoma accompanied by portal vein tumor thrombus using network meta-analysis. Ann Surg Treat Res. 2022; 103(5):280-289. PMC: 9678666. DOI: 10.4174/astr.2022.103.5.280. View

16.

Chen X, Qiu F, Wu Z, Zhang Z, Huang Z, Chen Y . Effects of location and extension of portal vein tumor thrombus on long-term outcomes of surgical treatment for hepatocellular carcinoma. Ann Surg Oncol. 2006; 13(7):940-6. DOI: 10.1245/ASO.2006.08.007. View

17.

Finn R, Qin S, Ikeda M, Galle P, Ducreux M, Kim T . Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020; 382(20):1894-1905. DOI: 10.1056/NEJMoa1915745. View

18.

Yang J, Kim J, Rhu J, Choi G, Kwon C, Joh J . Surgical Resection Is Preferred in Selected Solitary Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. Dig Surg. 2022; 39(1):42-50. DOI: 10.1159/000521827. View

19.

Bruix J, Raoul J, Sherman M, Mazzaferro V, Bolondi L, Craxi A . Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol. 2012; 57(4):821-9. DOI: 10.1016/j.jhep.2012.06.014. View

20.

Wei Z, Zhao J, Bi X, Zhang Y, Zhou J, Li Z . Neoadjuvant radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: a systematic review. Hepatobiliary Surg Nutr. 2022; 11(5):709-717. PMC: 9577988. DOI: 10.21037/hbsn-20-854. View